What Dimension Capital does

Dimension Capital is a multistage, research-oriented venture capital firm founded in 2022 that invests at the intersection of artificial intelligence and life sciences. The firm is headquartered in New York with a secondary office in San Francisco, California, and operates with a small team of 1-10 employees led by Founder and Managing Partner Adam Goulburn and co-founder Nan Li. Dimension Capital partners with companies developing AI-driven therapeutics, biologics platforms, computational biology tools, and epigenetic reprogramming technologies. The firm has built a portfolio concentrated in early- to growth-stage AI-biotech startups, including Earendil Labs (anti-TL1A antibody HXN-1001, $787M co-led round), Tamarind Bio (AI infrastructure for drug discovery), Convoke (biopharma workflow automation), NewLimit (AI-driven mRNA therapeutics for aging), and Fiveonefour (developer AI infrastructure).

The firm's business model follows standard venture capital economics: it earns management fees (typically ~2% on committed capital) and carries (typically 20% of fund profits) on the capital it manages. In December 2024, Dimension Capital raised a $500 million second fund targeting startups using AI to develop new medicines, just two years after its first fund. The firm distributes capital rather than products, sourcing deals through direct founder outreach, industry network relationships, research-driven deal identification, and co-investor partnerships with firms such as Kleiner Perkins, Sanofi, Founders Fund, and DST Global. Dimension Capital also operates Dimension Research, a Substack publication with over 2,000 subscribers that publishes analysis on frontier advances in life sciences and machine learning, functioning as a thought leadership and deal-sourcing channel.

Dimension Capital's go-to-market motion is enterprise field sales in character — high-touch, research-driven direct engagement with founders and co-investors — though it markets primarily through content (research publication), industry events, and social media rather than traditional demand generation. Revenue figures are not publicly disclosed, but management fee economics on disclosed fund size suggest annual revenues in the $10M-$25M range, with upside from carried interest on portfolio exits. The firm's vertical specialization in AI-biotech differentiates it from generalist VCs and aligns it with two of the most active capital pools in venture: artificial intelligence and life sciences.

Name

Dimension Capital

Legal name

Dimension Capital

Website

https://dimensioncap.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

Dimension Capital is a multistage venture capital firm founded in 2022 that invests in AI-biotech and life sciences startups developing novel therapeutics, biologics platforms, and computational biology tools. The firm manages a $500M second fund and operates offices in New York and San Francisco.

Ownership category

akta.pro rank

Product category

Life Sciences Venture Capital

NAICS

All Other Financial Investment Activities (52399), Portfolio Management and Investment Advice (523940)

SIC

Investors, Nec (6799), Investment Advice (6282)

akta.pro primary industry

Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)

Keywords

• Venture capital investing
• Life sciences investing
• AI biotech funding
• Multistage venture capital
• Early-stage investments

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. Investment Returns and Management Fees: Dimension Capital generates returns through equity appreciation in portfolio companies, realized through IPOs, acquisitions, and secondary transactions. The firm also earns management fees on its managed capital base, with typical VC fee structures of 2% on committed capital.

Go-to-market motion1 record

Marketing channels3 records

Core offering

Dimension Capital is a multistage, research-oriented venture capital firm that partners with companies at the intersection of science and compute, deploying equity capital into AI-biotech and life sciences startups from seed through growth stage. The firm raised a $500 million second fund in December 2024 dedicated to startups using artificial intelligence to develop new medicines, and supports portfolio companies with strategic guidance and industry network access.

Product overview

Dimension Capital is a multistage, research-oriented venture capital investment firm that partners with companies across the frontiers of science and compute. The firm primarily invests in AI-biotech and healthcare startups, having raised a $500 million second fund targeting startups using artificial intelligence to develop new medicines. As an investment firm rather than a product company, Dimension Capital does not offer standalone products or services to end customers.

Differentiator

Problem solved

Functional benefit

Products and services

• Dimension Capital Fund I Multistage venture capital fund investing across AI, life sciences, and frontier technology companies; LPs commit capital in exchange for exposure to the firm's investment portfolio.
• Dimension Capital Fund II ($500M AI-biotech fund) $500 million second fund dedicated to AI-biotech and life sciences startups; deploys equity from seed through growth stage into companies using AI for drug discovery, therapeutic development, and computational biology platforms.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Flagship Pioneering: Flagship Pioneering is a leading life sciences innovation platform that creates and funds biotech companies at scale. It competes for capital and talent in the same AI-biotech frontier that Dimension targets, though its model is more company-creation oriented.
• ARCH Venture Partners: ARCH is one of the largest and longest-tenured biotech-focused VCs, investing across the full life sciences spectrum from seed through public markets. It represents an incumbent competitor in the same AI-biotech adjacency that Dimension targets.
• Andreessen Horowitz (Bio + AI): a16z operates dedicated Bio/Health and AI funds that compete directly for the AI-biotech deals Dimension pursues. With far greater AUM, brand, and operating partners, it is a scaled incumbent competitor for both deals and LP allocations.

Direct peers

• Lux Capital: Lux Capital is a sector-focused VC firm with deep specialism at the intersection of AI, deep tech, and life sciences — the closest direct competitor to Dimension Capital's investment thesis. Notable for founding partner involvement in AI-biotech deals and a similar multistage investment approach.
• Khosla Ventures: Khosla Ventures invests aggressively across AI and healthcare/life sciences with a multistage mandate, directly overlapping with Dimension's core thesis. As one of the most established frontier-tech VCs, it competes for both AI-biotech deals and limited partner capital.
• Section 32: Section 32 is a venture firm founded by former Google Ventures head Bill Maris that focuses specifically on biotech, healthcare, and AI-driven life sciences — a near-direct peer to Dimension in mandate and stage. It invests across seed to growth, similar to Dimension's multistage approach.
• Kleiner Perkins: Kleiner Perkins is a frequent Dimension co-investor (led Convoke and NewLimit rounds alongside Dimension) and pursues overlapping frontier-tech and life sciences theses. As a legacy multi-stage firm, it competes for similar AI-biotech deals at the seed and growth stages.
• Founders Fund: Founders Fund participated in NewLimit's $130M Series B alongside Dimension and invests across frontier tech including biotech and AI. It competes for similar high-conviction, thesis-driven AI-biotech investments.
• AIX Ventures: AIX Ventures is an AI-focused venture firm with explicit exposure to AI applications in biotech and life sciences, closely mirroring Dimension's sector thesis. As a smaller, thesis-driven emerging manager, it is among the closest direct competitors.

Emerging players

• Y Combinator (Bio track): Y Combinator incubated Dimension's portfolio company Tamarind Bio and runs a dedicated bio track that sources many of the earliest AI-biotech startups. It functions as a feeder for downstream investors like Dimension and a partial competitor at the seed stage.

Market position

Competitive moat4 records

Key highlights6 records

Customer concentration

• Xx.com/_dimensioncap
• LinkedInlinkedin.com/company/dimensioncap

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments31 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dimension Capital